Genmab — September 2019

[E_L]

While 4-1BB is a known immune checkpoint target that is expressed on T cells and natural killer, or NK, cells, prior attempts to target 4-1BB with monoclonal antibodies have been severely limited by liver toxicities. Our 4-1BB targeting product candidates are designed to avoid toxicities by conditionally activating a 4-1BB receptor only together with the binding of either PD-L1 or CD40. We have initiated Phase 1/2a trials of GEN1046 (BNT311) and GEN1042 (BNT312) in solid tumors.

[E_L]

interesting on the liver toxicity which Jan also mentioned before

[E_L]

and also GEN1042 has initiated according to this

[E_L]

it was taken out of clinicaltrials a while ago, as you may remember. (I understand on a recent investor conference in Holland, Jan said that it is the next product candidate planned for the clinic)

[JohnW]

Are GEN1046 and GEN1042 both Genmab products?

[JohnW]

(hence the prefix?)

[E_L]

50:50 cost and profit share with Genmab

[E_L]

with GEN1046 it reads "executed by Genmab" so I guess Genmab mostly in charge

[E_L]

GEN1042 "We and Genmab began recruitment and screening for a Phase 1/2a trial of GEN1042 (BNT312) for the treatment of malignant solid tumors in August 2019." - so it
started

[Sukkeralf]

They pulled back the IND and made a CTA instead - so the trial on GEN1042 will be made in Europe

[E_L]

ah, ok, thanks

[E_L]

so i guess we keep following this one instead of clinicaltrials US https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-003716-47/DK

[Sukkeralf]

yes sir

[AaBforever]

Vi skal sikkert ned i 1270 igen.

[E_L]

Bryan, Garnier : GENMAB - BUY | DKK1450(+4%)

Data-Driven Medicine is getting more traction

Agreement to identify new disease targets/biomarkers
DDM getting more traction among the pharma/biotech industry
Recipe for success: network is a key

[Helge_LarsenPI-redaktør]

Et sundstegn at phama falder i kurs: https://penge.borsen.dk/artikel/1/387482/chef_aktieanalytiker_sundhedstegn_for_aktiemarkedet_at_novo_nordisk_falder.html

[Vitus]

Hvorfor skal vi ikke længere ned end 1270 igen ?

[Helge_LarsenPI-redaktør]

Fordi på 1.270 går Aab´s Bulls i minus.

[Vitus]

Det tror jeg nu ikke der bliver taget hensyn til....

[StockBull]

kun handlet 75000stk så 1270 er nok ikke realistisk her og nu. men ser helst vi slutter over 1350 for der skal nok ikke meget til for at få kursen under 1300 hvis vi går under 1330 idag